TD Cowen analyst Tyler Van Buren has maintained their neutral stance on MRNA stock, giving a Hold rating on October 17. Tyler Van ...

The biotech industry is buzzing with exciting changes, and a lot of it is thanks to one company: Moderna. Known for its COVID ...

Zylem Biosciences announced that Northwestern University has filed a lawsuit against Moderna (MRNA), alleging infringement of key patents ...

In recent years, the biotech industry has seen a lot of exciting changes, and much of that is thanks to one company: Moderna.

The latest trading session saw Moderna (MRNA) ending at $53.80, denoting a -0.55% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily loss of 0.18%. Elsewhere, ...

Moderna was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused ...

Northwestern University has filed a lawsuit against Moderna, alleging the company used its patented lipid nanoparticle ...

Zylem Biosciences, a company specializing in cancer and cardiovascular therapeutics, announced that Northwestern University ...

The Evanston college claims Moderna could not have developed the vaccine as quickly as it did in 2020 without its own ...

Discover why the stock prices of mRNA therapy creators BioNTech and Moderna have plummeted and whether they are still worth ...

Sanford C. Bernstein started coverage on shares of Moderna (NASDAQ:MRNA – Free Report) in a research note issued to investors ...

TD Cowen维持对Moderna股票(NASDAQ: MRNA)的"持有"评级，目标价保持在60.00美元不变。 该公司在生物科技板块第三季度财报预览前发布了这一更新，并对Moderna的财务模型进行了调整。